Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176716 | 0.84 | SCD (0.37) | EGLN1KDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL2178356 | 0.84 | EGLN1 (0.36) | EGLN1KDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL2179568 | 0.80 | EGLN1 (0.35) | EGLN1KDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL2177226 | 0.79 | MGAM (0.32) | EGLN1KDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL12408997 | 0.79 | EGLN1 (0.35) | EGLN1KDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL2181543 | 0.78 | ROCK2 (0.37) | EGLN1KDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL2177486 | 0.77 | EGLN1 (0.42) | EGLN1 | |
| SCHEMBL12408988 | 0.73 | ROCK2 (0.36) | EGLN1SCDROCK2PIM1GSK3B | |
| SCHEMBL12408990 | 0.72 | EGLN1 (0.41) | EGLN1SCD | |
| SCHEMBL2178963 | 0.71 | SCD (0.39) | EGLN1KDM4AKDM5CKDM4CKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350097-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2011-08-03 | — | — | EP | disclosed |
| US-20110166152-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166152-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, CPT1A | PPARA 130/4885EGLN1 1112/4885KDM4A 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.